SCHEMBL4130736

SCHEMBL4130736

CN(Cc1cc(-c2cncn2C)c(S(=O)(=O)c2ccccc2)s1)C(=O)O

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
IDO1 P14902 3/20 0.38
NAMPT P43490 1/20 0.34
L3MBTL1 Q9Y468 1/20 0.33
CYP17A1 P05093 1/20 0.33
APOBEC3A P31941 1/20 0.32
HDAC3 O15379 2/20 0.32
HDAC6 Q9UBN7 2/20 0.32
HDAC1 Q13547 1/20 0.32
HDAC2 Q92769 1/20 0.32
HDAC10 Q969S8 1/20 0.32
HDAC8 Q9BY41 1/20 0.32
NCOR2 Q9Y618 1/20 0.32
CYP3A4 P08684 1/20 0.32
HTR1A P08908 1/20 0.32
CYP2D6 P10635 1/20 0.32
DRD2 P14416 1/20 0.32
HTR7 P34969 1/20 0.32
HTR6 P50406 1/20 0.32
HPGDS O60760 1/20 0.32
FNTA P49354 2/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4118500 0.88 HTR2C (0.36) IDO1FNTAFNTBPLK1PGGT1B
SCHEMBL4130659 0.84 ITGB1 (0.38) NAMPTL3MBTL1HDAC8HTR6KMT2A
SCHEMBL4126163 0.80 PDK1 (0.36) NAMPTAPOBEC3AHTR6HDAC4
Fumaric Acid SCHEMBL4118145 0.80 IDO1 (0.36) IDO1NAMPTCYP17A1HDAC3HDAC6
Fumaric Acid SCHEMBL4118141 0.80 IDO1 (0.36) IDO1NAMPTCYP17A1HDAC3HDAC6
SCHEMBL4125901 0.76 NAMPT (0.35) NAMPTHDAC3HDAC6HDAC4
SCHEMBL4138201 0.75 GPBAR1 (0.37) NAMPTPOLB
SCHEMBL4126794 0.75 CA12 (0.39) NAMPTL3MBTL1HDAC3HDAC6HDAC1
SCHEMBL4132659 0.74 NAMPT (0.39) NAMPTKMT2ACA12CA1CA2
SCHEMBL4127140 0.73 NAMPT (0.33) NAMPTMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2190822-B1 5-MEMBERED HETEROCYCLIC COMPOUNDS AS PROTON PUMP INHIBITORS TAKEDA PHARMACEUTICAL (JP) 2014-12-31 EP disclosed
US-20090156642-A1 5-Membered heterocyclic compound TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-06-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090156642-A1 5-Membered heterocyclic compound CEL, PGA5, COG5 IDO1 3639/4885NAMPT 2129/4885L3MBTL1 4714/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.